Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL) has unveiled new corporate branding to reflect its transformation into a retina-focused company. The rebranding features a new logo with a circular "O" representing the eye and retina, along with a full-spectrum color palette symbolizing human vision.
The company's primary focus is on disrupting retinal disease treatment, particularly wet age-related macular degeneration (AMD), which affects 1.8 million people in the U.S. Their investigational therapy, AXPAXLI™ (OTX-TKI), aims to address the limitations of current treatments that require up to 12 injections yearly and often lead to complications like fibrosis and atrophy.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, OCUL gained 2.94%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience
BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's transformation to a retina-focused company.
Ocular Therapeutix Logo
Designed with visual accessibility at its core, the logo is science-based, transformative, and joyful. The circular “O” represents the eye and the retina, while the full-spectrum color palette captures the vibrancy of human vision and the richness of life it enables. The treatment of the “X” represents the intersection of where the company has been and where it is going.
“Retinal disease, including wet age-related macular degeneration (AMD), remains a leading cause of blindness due to the high burden and pulsatile nature of available treatments,” said Pravin U. Dugel, MD, Executive Chairman, President, and CEO of Ocular Therapeutix. “At Ocular, we aim to redefine the retina experience to reduce that burden in hopes of preserving vision for the long-term. Our new branding reflects the meaningful progress we’ve made, driven by the momentum of our SOL trials and our commitment to patients.”
Ocular Therapeutix Anthem Video
Ocular Therapeutix: Retina Experience Redefined
A Media Snippet accompanying this announcement is available in this link.
Ocular’s top priority is to disrupt retinal disease treatment paradigms, starting with wet AMD which affects 1.8 million people in the U.S. alone. Current treatment options may require up to 12 injections per year, creating a heavy burden on patients and care partners that can lead to treatment discontinuation and poor long-term outcomes. With today’s pulsatile treatments, one in four patients develop fibrosis within two years and atrophy within five years.
Ocular Therapeutix’ investigational therapy, AXPAXLI™ (also known as OTX-TKI), is an axitinib hydrogel administered by intravitreal injection that has the potential to dramatically improve durability and long-term outcomes for patients with wet AMD and other retinal diseases.
The new corporate branding is now live across Ocular’s website, social media channels, and internal platforms, and will make its congress debut at the upcoming American Society of Retina Specialists (ASRS) conference, marking an exciting new chapter for the Company.
Explore the new corporate branding on our website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company via its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c36052c2-ba6b-4175-806e-728f3e09ac1b
FAQ
What is the significance of Ocular Therapeutix (OCUL) new branding announcement?
What is AXPAXLI and how does it address wet AMD treatment challenges?
How many people are affected by wet AMD in the United States?
What are the current challenges in wet AMD treatment that Ocular Therapeutix aims to address?
